title: Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review.
abstract: Surgery following neoadjuvant chemoradiotherapy (NCRT) is a common multidisciplinary treatment for resectable esophageal cancer (EC). After analyzing 12 randomized controlled trials (RCTs), we discuss the key issues of surgery in the management of resectable EC. Along with chemoradiotherapy, NCRT is recommended for patients with squamous cell carcinoma (SCC) and adenocarcinoma (AC), and most chemotherapy regimens are based on cisplatin, fluorouracil (FU), or both (CF). However, taxane-based schedules or additional studies, together with newer chemotherapies, are warranted. In nine clinical trials, post-operative complications were similar without significant differences between two treatment groups. In-hospital mortality was significantly different in only 1 out of 10 trials. Half of the randomized trials that compare NCRT with surgery in EC demonstrate an increase in overall survival or disease-free survival. NCRT offers a great opportunity for margin negative resection, decreased disease stage, and improved loco-regional control. However, NCRT does not affect the quality of life when combined with esophagectomy. Future trials should focus on the identification of optimum regimens and selection of patients who are most likely to benefit from specific treatment options.
authors.affiliation: Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Duan
authors.affiliation: Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Tang
authors.affiliation: Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
authors.forename: Zhen-Tao
authors.initials: ZT
authors.lastname: Yu
keywords: Esophageal cancer (EC); chemoradiotherapy; esophagectomy; neoadjuvant therapy; randomized controlled clinical trials; review